Premium
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies primarily for rare and orphan diseases. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to red... Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies primarily for rare and orphan diseases. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its products in the pipeline include Diverticulosis and Cell Sheet Engineering. Show more
NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the June 23rd Life...
NEW YORK, March 30, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced that the presentations from its inaugural conference are now available for on-demand viewing at...
NEW YORK, March 24, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its inaugural event for public and private companies, investors and industry...
TORRANCE, Calif., March 23, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB:EMMA), a leader in sickle cell disease treatment, today announced that Dr. Yutaka Niihara, M.D., M.P.H...
Emmaus Life Sciences to be Delisted from Nasdaq Stock Market Following Hearing -- Company Committed to Listing on Major Exchange -- PR Newswire TORRANCE, Calif., Sept. 10, 2019 TORRANCE, Calif...
Emmaus Life Sciences Granted European Patent for use of Pharmaceutical-grade L-glutamine in Treating Diverticulosis Related patents granted in the United States, Japan, Australia, Mexico, China...
Emmaus Life Sciences Adds Oncology Supply as Distributor PR Newswire TORRANCE, Calif., Aug. 28, 2019 TORRANCE, Calif., Aug. 28, 2019 /PRNewswire/ -- Emmaus Life Sciences, Inc. (Nasdaq: EMMA), a...
Emmaus Life Sciences to Host "Sideline Sickle Cell" Community Town Hall with ASAP and FSCDR in South Florida Campaign spokesperson Solomon Wilcots will be joined by fellow NFL Veteran...
Emmaus Life Sciences Reports Sharply Improved 2019 Second Quarter Financial Results -- Net Revenues Increase 128% Year-Over-Year, as FDA-Approved Treatment for Sickle Cell Disease Rolls Out -- PR...
Emmaus Life Sciences Reiterates Financial Benefits from Recent Merger -- Company to Announce Second Quarter Financial Results Next Week -- PR Newswire TORRANCE, Calif., Aug. 8, 2019 TORRANCE...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
